Jason Kessler1, Kimberly Nucifora2, Lingfeng Li2, Lauren Uhler2, Scott Braithwaite2. 1. Department of Population Health, New York University School of Medicine, New York, NY, USA. Electronic address: Jason.Kessler@nyumc.org. 2. Department of Population Health, New York University School of Medicine, New York, NY, USA.
Abstract
OBJECTIVES: Attrition from care among HIV infected patients can lead to poor clinical outcomes. Our objective was to evaluate hypothetical interventions seeking to improve retention-in-care (RIC) for HIV-infected patients in East Africa, asking whether they could offer favorable value compared to earlier ART initiation. METHODS: We used a micro-simulation model to analyze two RIC focused strategies within an East African HIV treatment program--"risk reduction," defined as intervention(s) that decrease the risk of attrition from care; and "outreach," defined as interventions that find patients and relink them with care. We compared this to earlier ART treatment as a measure of the potential health benefits forgone (e.g., opportunity cost). RESULTS: Reducing attrition by 40% at an average cost of $10 per person remains a less efficient use of resources compared to ensuring full access to ART (cost- effectiveness ratio $1300 vs $3700) for ART eligible patients. An outreach intervention had limited clinical benefit in our simulation. If intervention costs are <$10 per person, however, an intervention able to achieve a 40% (or greater) reduction in attrition may be a cost-effective next implementation option following implementation of earlier ART treatment. CONCLUSIONS: Our results suggest that programs should consider retention focused programs once they have already achieved high degrees of ART coverage among eligible patients. It is important that decision makers understand the epidemiology and associated outcomes of those patients who are classified as lost to follow up in their systems prior to implementation in order to achieve the highest value.
OBJECTIVES: Attrition from care among HIV infectedpatients can lead to poor clinical outcomes. Our objective was to evaluate hypothetical interventions seeking to improve retention-in-care (RIC) for HIV-infectedpatients in East Africa, asking whether they could offer favorable value compared to earlier ART initiation. METHODS: We used a micro-simulation model to analyze two RIC focused strategies within an East African HIV treatment program--"risk reduction," defined as intervention(s) that decrease the risk of attrition from care; and "outreach," defined as interventions that find patients and relink them with care. We compared this to earlier ART treatment as a measure of the potential health benefits forgone (e.g., opportunity cost). RESULTS: Reducing attrition by 40% at an average cost of $10 per person remains a less efficient use of resources compared to ensuring full access to ART (cost- effectiveness ratio $1300 vs $3700) for ART eligible patients. An outreach intervention had limited clinical benefit in our simulation. If intervention costs are <$10 per person, however, an intervention able to achieve a 40% (or greater) reduction in attrition may be a cost-effective next implementation option following implementation of earlier ART treatment. CONCLUSIONS: Our results suggest that programs should consider retention focused programs once they have already achieved high degrees of ART coverage among eligible patients. It is important that decision makers understand the epidemiology and associated outcomes of those patients who are classified as lost to follow up in their systems prior to implementation in order to achieve the highest value.
Authors: Gregory P Bisson; Ian Frank; Robert Gross; Vincent Lo Re; Jordan B Strom; Xingmei Wang; Mpho Mogorosi; Tendani Gaolathe; Ndwapi Ndwapi; Harvey Friedman; Brian L Strom; Diana Dickinson Journal: AIDS Date: 2006-06-12 Impact factor: 4.177
Authors: R Scott Braithwaite; Amy C Justice; Chung-Chou H Chang; Jennifer S Fusco; Stephen R Raffanti; John B Wong; Mark S Roberts Journal: Am J Med Date: 2005-08 Impact factor: 4.965
Authors: T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray Journal: N Engl J Med Date: 2000-03-30 Impact factor: 91.245
Authors: Papa S Sow; Leander F Otieno; Emmanuel Bissagnene; Cissy Kityo; Ruurd Bennink; Philippe Clevenbergh; Ferdinand W N M Wit; Esther Waalberg; Tobias F Rinke de Wit; Joep M Lange Journal: J Acquir Immune Defic Syndr Date: 2007-03-01 Impact factor: 3.731
Authors: Molly F Franke; Felix Kaigamba; Adrienne R Socci; Massudi Hakizamungu; Anita Patel; Emmanuel Bagiruwigize; Peter Niyigena; Kelly D C Walker; Henry Epino; Agnes Binagwaho; Joia Mukherjee; Paul E Farmer; Michael L Rich Journal: Clin Infect Dis Date: 2012-12-18 Impact factor: 9.079
Authors: R Scott Braithwaite; Mark S Roberts; Chung Chou H Chang; Matthew Bidwell Goetz; Cynthia L Gibert; Maria C Rodriguez-Barradas; Steven Shechter; Andrew Schaefer; Kimberly Nucifora; Robert Koppenhaver; Amy C Justice Journal: Ann Intern Med Date: 2008-02-05 Impact factor: 25.391
Authors: Kathrin Zürcher; Anne Mooser; Nanina Anderegg; Olga Tymejczyk; Margaret J Couvillon; Denis Nash; Matthias Egger Journal: Trop Med Int Health Date: 2017-02-20 Impact factor: 2.622
Authors: Peter F Rebeiro; Giorgos Bakoyannis; Beverly S Musick; Ronald S Braithwaite; Kara K Wools-Kaloustian; Winstone Nyandiko; Fatma Some; Paula Braitstein; Constantin T Yiannoutsos Journal: J Acquir Immune Defic Syndr Date: 2017-10-01 Impact factor: 3.731
Authors: Andrew N Phillips; Valentina Cambiano; Fumiyo Nakagawa; Loveleen Bansi-Matharu; Papa Salif Sow; Peter Ehrenkranz; Deborah Ford; Owen Mugurungi; Tsitsi Apollo; Joseph Murungu; David R Bangsberg; Paul Revill Journal: PLoS One Date: 2016-12-15 Impact factor: 3.240
Authors: Anik R Patel; Jason Kessler; R Scott Braithwaite; Kimberly A Nucifora; Harsha Thirumurthy; Qinlian Zhou; Richard T Lester; Carlo A Marra Journal: Medicine (Baltimore) Date: 2017-02 Impact factor: 1.889
Authors: Anna Bershteyn; Lise Jamieson; Hae-Young Kim; Ingrida Platais; Masabho P Milali; Edinah Mudimu; Debra Ten Brink; Rowan Martin-Hughes; Sherrie L Kelly; Andrew N Phillips; Loveleen Bansi-Matharu; Valentina Cambiano; Paul Revill; Gesine Meyer-Rath; Brooke E Nichols Journal: Lancet Glob Health Date: 2022-09 Impact factor: 38.927
Authors: Geoffrey Fatti; Debra Jackson; Ameena E Goga; Najma Shaikh; Brian Eley; Jean B Nachega; Ashraf Grimwood Journal: J Int AIDS Soc Date: 2018-02 Impact factor: 5.396
Authors: Lusungu Chirambo; Martha Valeta; Tifiness Mary Banda Kamanga; Alinane Linda Nyondo-Mipando Journal: BMC Public Health Date: 2019-10-28 Impact factor: 3.295